Daniel Lindholm


Affiliation: Uppsala University Hospital
Country: Sweden


  1. Lindholm D, Storey R, Christersson C, Halvorsen S, Grove E, Braun O, et al. Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. Am Heart J. 2015;170:465-70 pubmed publisher
    ..This trial will determine if adenosine antagonism by caffeine can alleviate ticagrelor-related dyspnea, without impairing the antiplatelet effect of ticagrelor. ..
  2. Lindholm D, James S. Bioresorbable Stents in PCI. Curr Cardiol Rep. 2016;18:74 pubmed publisher
    ..Further development and longer-term studies are needed before the routine implementation of bioresorbable stents in clinical practice. ..
  3. Lindholm D, James S, Bertilsson M, Becker R, Cannon C, Giannitsis E, et al. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017;63:573-584 pubmed publisher
    ..This information may be useful for selection of patients who might benefit from more intense and/or prolonged antithrombotic treatment. ClinicalTrials.gov Identifier: NCT00391872. ..
  4. Lindholm D, Lindback J, Armstrong P, Budaj A, Cannon C, Granger C, et al. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017;70:813-826 pubmed publisher
    ..The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial [STABILITY]; NCT00799903). ..
  5. Lindholm D, Hagström E, James S, Becker R, Cannon C, Himmelmann A, et al. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc. 2017;6: pubmed publisher
    ..GDF-15 levels may therefore be useful as part of decision support concerning long-term antithrombotic treatment in patients post-ACS. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872. ..